Align Technology (ALGN) Investor Day 2025 summary
Event summary combining transcript, slides, and related documents.
Investor Day 2025 summary
3 Feb, 2026Strategic vision and market opportunity
Focus on making digital tooth movement the standard of care, expanding from orthodontics to comprehensive dentistry globally.
75% of the global population has malocclusion, representing a vast untapped market for clear aligners and digital dental solutions.
Emphasis on growing the teen and kids segment, with significant investments in products like Invisalign First and palate expanders.
Expansion into general practitioner (GP) and DSO channels, with tailored products and digital workflows to drive adoption.
Geographic diversification with strong growth in APAC, EMEA, and emerging markets, supported by local manufacturing and education initiatives.
Technology and product innovation
Continued leadership in 3D printing, AI, and machine learning, enabling mass customization and rapid treatment planning.
Direct fabrication (direct fab) 3D printing platform to reduce material waste, lower costs, and enable new device designs.
iTero Lumina scanner redefines intraoral scanning with faster, more accurate, and integrated diagnostics and restorative workflows.
Exocad integration empowers labs and GPs to incorporate tooth movement into restorative procedures, preserving enamel and improving outcomes.
Digital tools like ClinCheck, Outcome Simulator Pro, and virtual care apps enhance patient engagement, compliance, and practice efficiency.
Financial guidance and operational efficiency
2025 guidance: revenue growth of 3.5%-5.5% and clear aligner volume growth of about 5%, assuming no macroeconomic improvement.
2026-2028 outlook: 5%-15% annual revenue and volume growth, driven by new products, market expansion, and operational improvements.
ASPs expected to decline slightly due to product mix and emerging market growth, but gross margins to improve with scale and efficiency.
Commitment to maintaining operating margins at or above 25% long-term, with gross margins targeted above 73% as scale increases.
Capital allocation prioritizes business investment, innovation, and shareholder returns, including a new $1 billion share buyback.
Latest events from Align Technology
- Voting standard for Proposal 4 clarified; majority approval of shares present or represented required.ALGN
Proxy filing17 Apr 2026 - Record Q4 and FY2025 revenues, strong Clear Aligner and DSO growth, and positive 2026 outlook.ALGN
Q4 202517 Apr 2026 - Record revenues, robust governance, and enhanced shareholder rights highlight this year's proxy.ALGN
Proxy filing7 Apr 2026 - Virtual Annual Meeting to address director elections, compensation, auditor, and bylaw proposals.ALGN
Proxy filing7 Apr 2026 - Record revenues, robust governance, and enhanced shareholder rights highlight this year's proxy.ALGN
Proxy filing27 Mar 2026 - Broad-based growth, strong DSO performance, and stable outlook drive confidence for 2026.ALGN
Barclays 28th Annual Global Healthcare Conference11 Mar 2026 - Strong growth in Europe and APAC, with product innovation and efficiency boosting margins.ALGN
Leerink Global Healthcare Conference 202610 Mar 2026 - Q2 2024 revenue up 2.6% to $1.03B; margin pressured by FX, mix, and legal settlement.ALGN
Q2 20243 Feb 2026 - Q1 2024 growth fueled by AI, 3D printing, and new digital orthodontic products.ALGN
The 44th Annual William Blair Growth Stock Conference31 Jan 2026